Study Examines Multiple Methods of Testing Driving Impairment after Consuming Cannabis
A recent study reported results from a University of California San Diego Center for Medicinal Cannabis Research study on cannabis consumption and its effects on driving ability.
A study published May 25, 2023 in the journal Clinical Chemistry evaluated the effects of tetrahydrocannabinol (THC) on driving performance (1). The placebo-controlled randomized double-blinded protocol studied 191 participants who were instructed to smoke as much or as little of a THC cigarette that was either a placebo or contained delta-9-tetrahydrocannabinol (1).
“The relationship between blood THC concentrations and crash risk is not established, but there is a clear understanding that THC impairs driving performance in many, but not necessarily all, individuals,” the introduction stated (1). “The question that remains is how to best identify drivers who are impaired by cannabis.”
After smoking, the participants gave blood, oral fluids (OF), and breath samples. Law enforcement officers from the California Highway Patrol or other agencies performed the sobriety tests on the participants and classified them as impaired or not impaired.
“In the largest trial to date involving experienced users smoking cannabis, there was no correlation between THC (and related metabolites/cannabinoids) in blood, OF, or breath and driving performance,” the researchers concluded (1). “Our data support the current practice in many areas of the United States that requires officer observations of impairment along with toxicology testing before prosecuting drivers for being under the influence.”
The researchers suggested evidence for using oral fluids as opposed to blood samples in reducing the likelihood of false accusations of impairment, and stated that more research is needed on the comparison between exams from drug recognitions experts and field sobriety tests (1).
Reference
- Fitzgerald, R. L.; Umlauf, A.; Hubbard, J. A.; Hoffman, M. A.; Sobolesky, P. M.; Ellis, S. E.; Grelotti, D. J.; Suhandynata, R. T.; Huestis, M. A.; Grant, I.; Marcotte, T. D. Driving under the Influence of Cannabis: Impact of Combining Toxicology Testing with Field Sobriety Tests. Clinical Chemistry 2023.
Ep 25: Cannabis Quality Differentiation Beyond Cannabinoid Content
February 28th 2025In this latest installment of Noid Knowledge we are joined by Julie Kowalski, a leading mind in analytical chemistry and cannabis testing. Julie has arranged a very compelling symposium for Pittcon entitled Cannabis Aroma: Advances and Challenges in Determining and Commercializing Cannabis Product Quality Attributes. It is taking place on Wednesday, March 5, 2025, starting at 9:30 AM in room 209. The session features top notch speakers, including several previous guests of this show, and yours truly, discussing the next generation of quality assessment in cannabis.
The Cost of Compliance in the Cannabis Industry
April 1st 2025The financial and reputational risks of non-compliance far outweigh the upfront investment required to establish robust compliance systems. This blog explores the true cost of compliance, what non-compliance can mean for a business, and why investing in compliance is a proactive, strategic decision rather than a burdensome expense.
Ep 24, Part III: Data Transparency in Cannabis Testing with Yasha Kahn
December 26th 2024In the final part of this episode, Evan Friedmann and Yasha Kahn discuss the need for a national entity to centralize cannabis data collection, moving from snapshot data to continuous updates. They emphasize the importance of accurate lab data and adverse event tracking, suggesting QR codes on packaging to report issues. Yasha suggests harsher consequences for result manipulation and suggests collaboration between state departments and federal entities to support underfunded regulators. They also discuss the potential benefits of off-the-shelf testing and the importance of stability testing. Finally, Yasha shares his top three reading recommendations for the audience.
